Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Niger J Clin Pract ; 22(4): 516-520, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30975956

RESUMO

BACKGROUND: Impaired quality of life can be seen in the spouses of the obstructive sleep apnea syndrome (OSAS) patients. The main aim of the study is to assess the quality of life, anxiety, and depression in the spouses of the OSAS patients. MATERIALS AND METHODS: A total of 100 OSAS patients and their spouses were included in the study. The demographic features of patients and the findings related to their disease and relevant clinical conditions were recorded. The quality of life of the spouses was evaluated by Short Form-36, their depression levels by Beck's depression inventory (BDI), anxiety levels by Beck's anxiety inventory, and the hospital anxiety and depression scale (HADS). RESULTS: About 33% and 26% of patients' spouses showed depression by BDI and HADS, respectively; 14% of them showed anxiety by hospital anxiety scale. Among the subparameters of quality of life in spouses of patients who receive PAP (positive airway pressure) treatment, scores of physical condition, physical role restrictions, and role restrictions due to emotional problems were significantly higher than the ones in spouses of nontreated patients (P < 0.05). Depression scores of spouses of patients who use PAP were significantly lower than the ones who do not use the device (P < 0.05). A significant difference was not found between the two groups by means of anxiety scores (P > 0.05). CONCLUSION: The use of continuous PAP improves not only the quality of life for OSAS patients but also for their spouses and reduces the spouses' depression risk.


Assuntos
Ansiedade/diagnóstico , Depressão/diagnóstico , Qualidade de Vida/psicologia , Apneia Obstrutiva do Sono/diagnóstico , Cônjuges/psicologia , Adulto , Ansiedade/epidemiologia , Ansiedade/psicologia , Depressão/epidemiologia , Depressão/psicologia , Feminino , Humanos , Masculino , Saúde Mental , Pessoa de Meia-Idade , Estudos Prospectivos , Escalas de Graduação Psiquiátrica , Apneia Obstrutiva do Sono/psicologia , Turquia/epidemiologia
2.
Clin Oncol (R Coll Radiol) ; 19(7): 494-8, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17513096

RESUMO

AIMS: An elevated plasma D-dimer level indicates the activation of coagulation and fibrinolysis. In the present study, we investigated the association of pre-treatment haemostatic parameters (D-dimer, fibrinogen and prothrombin fragment 1+2) with clinicopathological parameters and outcome in patients with lung cancer. MATERIALS AND METHODS: Plasma levels of D-dimer and other parameters were measured in 78 evaluable patients with lung cancer (60 non-small cell lung cancers, 18 small cell lung cancers). At diagnosis, 35 patients (44.9%) were locally advanced stage (IIIA/B) and 43 patients (55.1%) had metastatic disease (IV). Multivariate statistical analysis was carried out using Cox's proportional hazards model. The receiver operating characteristic curve was used to determine the cut-off values for D-dimer, fibrinogen and prothrombin fragment 1+2. RESULTS: The median survival for all patients was 264 days (95% confidence interval 200-328 days). A significant association between the plasma levels of D-dimer and the response to chemotherapy was observed (P=0.03). With the univariate analysis, tumour stage, pre-treatment plasma levels of D-dimer, fibrinogen, platelet count, lactate dehydrogenase concentration and Karnofsky performance status were predictive for survival. With the multivariate analysis (P< or =0.1), the plasma level of D-dimer (P<0.001), tumour stage (P=0.01) and Karnofsky performance status (P=0.02) were identified as independent predictive factors. The median survival times were 405 days (95% confidence interval 165-644 days) and 207 days (95% confidence interval 146-267 days, P<0.001), respectively, for patients with a low D-dimer level (< or =0.65 microg/ml) and a high D-dimer level (>0.65 microg/ml). CONCLUSIONS: Elevated plasma levels of D-dimer in patients with lung cancer are associated with decreased survival and a poor response to treatment. Pre-treatment for the D-dimer level may be useful in the prediction of survival and the response to treatment.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/sangue , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma de Células Pequenas/sangue , Carcinoma de Células Pequenas/mortalidade , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/tratamento farmacológico , Feminino , Fibrinogênio/análise , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Prognóstico , Análise de Sobrevida
3.
Yonsei Med J ; 41(3): 340-4, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10957888

RESUMO

The efficacy and safety of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia were compared in an open randomized trial. Eighty-six male patients, doing their obligatory military service, ranging between 19 and 24 years of age (mean 20), were randomly treated: 29 with clarithromycin 500 mg 12-hourly, 30 with roxithromycin 150 mg 12-hourly, and 27 with erythromycin stearate 500 mg 6-hourly, each course being administered for 10 days. Seventy-eight patients were able to be evaluated for efficacy, 28 receiving clarithromycin, 28 roxithromycin, and 22 erythromycin stearate. There were no significant differences among the groups in terms of clinical success rates (clinical cure or improvement: 89% for clarithromycin, 82% for roxithromycin, and 73% for erythromycin stearate, p = 0.32). However, we found that there were significant differences among the groups in terms of clinical cure rates (75% for clarithromycin, 64% for roxithromycin, and 41% for erythromycin stearate, p = 0.04). Adverse events, mostly gastrointestinal, caused discontinuation of treatment in 3.4% of the patients in the clarithromycin group, in 6.6% of the patients in the roxithromycin group, and in 18.5% of the patients in the erythromycin stearate group. The results indicate that there were no statistically significant differences among the three treatment groups in terms of clinical success rates, but that clarithromycin and roxithromycin were better tolerated.


Assuntos
Antibacterianos/uso terapêutico , Claritromicina/uso terapêutico , Eritromicina/análogos & derivados , Eritromicina/uso terapêutico , Pneumonia/tratamento farmacológico , Pneumonia/fisiopatologia , Roxitromicina/uso terapêutico , Adulto , Antibacterianos/efeitos adversos , Claritromicina/efeitos adversos , Eritromicina/efeitos adversos , Feminino , Humanos , Masculino , Pneumonia/diagnóstico por imagem , Pneumonia/microbiologia , Radiografia Torácica , Roxitromicina/efeitos adversos
4.
Thorax ; 51(4): 397-402, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8733492

RESUMO

BACKGROUND: Although chest radiographs usually provide adequate information for the diagnosis of active pulmonary tuberculosis, minimal exudative tuberculosis can be overlooked on standard chest radiographs. The aim of the present study was to assess the findings of active pulmonary tuberculosis on high resolution computed tomographic (HRCT) scans, and to evaluate their possible use in determining disease activity. METHODS: Thirty two patients with newly diagnosed active pulmonary tuberculosis and 34 patients with inactive pulmonary tuberculosis were examined. The diagnosis of active pulmonary tuberculosis was based on positive acid fast bacilli in sputum and bronchial washing smears or cultures and/or changes on serial radiographs obtained during treatment. RESULTS: With HRCT scanning centrilobular lesions (n = 29), "tree-in-bud" appearance (n = 23), and macronodules 5-8 mm in diameter (n = 22) were most commonly seen in cases of active pulmonary tuberculosis. HRCT scans showed fibrotic lesions (n = 34), distortion of bronchovascular structures (n = 32), emphysema (n = 28), and bronchiectasis (n = 24) in patients with inactive tuberculosis. CONCLUSIONS: Centrilobular densities in and around the small airways and "tree-in-bud" appearances were the most characteristic CT features of disease activity. HRCT scanning clearly differentiated old fibrotic lesions from new active lesions and demonstrated early bronchogenic spread. These findings may be of value in decisions on treatment.


Assuntos
Pulmão/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Tuberculose Pulmonar/diagnóstico por imagem , Doença Aguda , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...